X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs VENUS REMEDIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH VENUS REMEDIES PANACEA BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x 136.4 -896.4 - View Chart
P/BV x 3.0 0.3 1,155.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
VENUS REMEDIES
Mar-16
PANACEA BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs149218 68.2%   
Low Rs8282 100.2%   
Sales per share (Unadj.) Rs84.1365.6 23.0%  
Earnings per share (Unadj.) Rs-18.31.5 -1,231.9%  
Cash flow per share (Unadj.) Rs-6.737.9 -17.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7382.5 21.9%  
Shares outstanding (eoy) m61.2511.44 535.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.4 334.5%   
Avg P/E ratio x-6.3101.0 -6.2%  
P/CF ratio (eoy) x-17.24.0 -435.7%  
Price / Book Value ratio x1.40.4 351.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,717 412.1%   
No. of employees `0002.81.0 269.6%   
Total wages/salary Rs m1,449324 446.7%   
Avg. sales/employee Rs Th1,874.14,100.7 45.7%   
Avg. wages/employee Rs Th527.0318.0 165.7%   
Avg. net profit/employee Rs Th-407.716.7 -2,446.5%   
INCOME DATA
Net Sales Rs m5,1544,183 123.2%  
Other income Rs m10020 496.5%   
Total revenues Rs m5,2544,203 125.0%   
Gross profit Rs m-766812 -94.4%  
Depreciation Rs m711417 170.6%   
Interest Rs m1,503380 395.7%   
Profit before tax Rs m-2,88135 -8,206.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1718 92.8%   
Profit after tax Rs m-1,12117 -6,595.9%  
Gross profit margin %-14.919.4 -76.6%  
Effective tax rate %-0.651.6 -1.1%   
Net profit margin %-21.80.4 -5,353.2%  
BALANCE SHEET DATA
Current assets Rs m3,8102,771 137.5%   
Current liabilities Rs m8,3651,931 433.1%   
Net working cap to sales %-88.420.1 -440.5%  
Current ratio x0.51.4 31.8%  
Inventory Days Days156125 124.5%  
Debtors Days Days6754 125.1%  
Net fixed assets Rs m14,4805,328 271.8%   
Share capital Rs m61114 53.6%   
"Free" reserves Rs m9034,177 21.6%   
Net worth Rs m5,1274,376 117.2%   
Long term debt Rs m5,8321,911 305.2%   
Total assets Rs m19,4338,428 230.6%  
Interest coverage x-0.91.1 -83.9%   
Debt to equity ratio x1.10.4 260.5%  
Sales to assets ratio x0.30.5 53.4%   
Return on assets %2.04.7 41.7%  
Return on equity %-21.90.4 -5,629.8%  
Return on capital %3.66.6 55.1%  
Exports to sales %24.50-   
Imports to sales %10.220.5 49.6%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525858 61.1%   
Fx inflow Rs m1,5390-   
Fx outflow Rs m942858 109.8%   
Net fx Rs m597-858 -69.6%   
CASH FLOW
From Operations Rs m599469 127.8%  
From Investments Rs m-43829 -1,499.7%  
From Financial Activity Rs m-303-464 65.3%  
Net Cashflow Rs m-14135 -409.6%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.2 333.3%  
FIIs % 1.3 0.6 224.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 66.4 35.5%  
Shareholders   10,259 20,121 51.0%  
Pledged promoter(s) holding % 35.1 36.4 96.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - FRESENIUS KABI ONCO. COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS